Association between circulating thrombopoietin levels and cardiovascular risk prediction scores in renal transplant recipients

American Journal of Nephrology

Volumn 41, Issue 2, 2015, Pages 147-155

  Mansell, Holly ^a   Elmoselhi, Hamdi ^b   Shoker, Ahmed ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cardiovascular risk prediction; Cytokines; Inflammation; Kidney transplant; Thrombopoietin

Indexed keywords

THROMBOPOIETIN; CREATININE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UREA;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FLUOROIMMUNOASSAY; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SMOKING; AGE; AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; AGE FACTORS; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SMOKING; STROKE VOLUME; THROMBOPOIETIN; UREA;

EID: 84926172920     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000377641     Document Type: Article

References (37)

1. Ojo AO: Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603-611
2. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(12 suppl): S16-S23
3. US Renal Data System: USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013. http://www. usrds.org/atlas.aspx (accessed June 23, 2014)
4. Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA: Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997; 12: 1672-1679
5. Krämer BK, Zülke C, Kammerl MC, Schmidt C, Hengstenberg C, Fischereder M, Marienhagen J; European Tacrolimus vs. Cyclosporine Microemulsion Renal Transplantation Study Group: Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3: 982-987
6. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B: Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75: 1341-1346
7. Shirali AC, Bia MJ: Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008; 3: 491-504
8. Zernecke A, Weber C: Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 2010; 86: 192-201
9. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damås JK: Chemokines in cardiovascular risk prediction. Thromb Haemost 2007; 97: 748-754
10. Mansell H, Stewart SA, Shoker A: Validity of cardiovascular risk prediction models in kidney transplant recipients. ScientificWorld-Journal 2014; 2014: 750579
11. Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED, Kasiske BL; PORT Investigators: Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study. Am J Transplant 2010; 10: 338-353
12. Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellström B: A cardiovascular risk calculator for renal transplant recipients. Transplantation 2012; 94: 57-62
13. Fellström B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, Gimpelewicz C, Holdaas H; ALERT Study Group: Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5: 1986-1991
14. Soveri I, Snyder J, Holdaas H, Holme I, Jardine AG, L'Italien GJ, Fellström B: The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. Transplantation 2013; 95: 142-147
15. De Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, et al: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-538
16. Lupia E, Goffi A, Bosco O, Montrucchio G: Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases. Mediators Inflamm 2012; 2012: 390892
17. Cardier JE, Dempsey J: Thrombopoietin and its receptor, c-Mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells. Blood 1998; 91: 923-929
18. Zhang J, Freyer D, Rung O, Im AR, Hoffmann O, Dame C: Inflammation stimulates thrombopoietin (Tpo) expression in rat brain-derived microvascular endothelial cells, but suppresses Tpo in astrocytes and microglia. J Interferon Cytokine Res 2010; 30: 465-469
19. Cardier JE: Effects of megakaryocyte growth and development factor (thrombopoietin) on liver endothelial cells in vitro. Microvasc Res 1999; 58: 108-113
20. Lupia E, Bosco O, Goffi A, Poletto C, Locatelli S, Spatola T, Cuccurullo A, Montrucchio G: Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis 2010; 210: 314-319
21. Szanto S: Smoking and atherosclerosis. Br Med J 1967; 3: 178
22. Altun B, Usalan C, Haznedaroglu IC, Arici M, Ulusoy S, Erdem Y, Yasavul U, Turgan C, Caglar S, Kirazli S: Thrombopoietin and thrombospondin in renal allograft recipients. Blood Coagul Fibrinolysis 1999; 10: 233-237
23. Stockelberg D, Andersson P, Björnsson E, Björk S, Wadenvik H: Plasma thrombopoietin levels in liver cirrhosis and kidney failure. J Intern Med 1999; 246: 471-475
24. Linthorst GE, Folman CC, van Olden RW, von dem Borne AE: Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J 2002; 3: 38-42
25. Ando M, Iwamoto Y, Suda A, Tsuchiya K, Nihei H: New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels. Blood 2001; 97: 915-921
26. Jüttner B, Brock J, Weissig A, Becker T, Studzinski A, Osthaus WA, Bornscheuer A, Scheinichen D: Dependence of platelet function on underlying liver disease in orthotopic liver transplantation. Thromb Res 2009; 124: 433-438
27. Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, Burroughs AK: Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999; 44: 754-758
28. Balcik ÖS, Bilen S, Ulusoy EK, Akdeniz D, Uysal S, Ikizek M, Ak F, Kosar A: Thrombopoietin and mean platelet volume in patients with ischemic stroke. Clin Appl Thromb Hemost 2013; 19: 92-95
29. Larsen SB, Grove EL, Hvas AM, Kristensen SD: Platelet turnover in stable coronary artery disease-influence of thrombopoietin and low-grade inflammation. PLoS One 2014; 9:e85566
30. Lupia E, Bosco O, Bergerone S, Dondi AE, Goffi A, Oliaro E, Cordero M, Del Sorbo L, Trevi G, Montrucchio G: Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina. J Am Coll Cardiol 2006; 48: 2195-2203
31. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E: Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1999; 33: 634-639
32. Senaran H, Ileri M, Altinba? A, Koar A, Yetkin E, Oztürk M, Karaaslan Y, Kirazli S: Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol 2001; 24: 405-408
33. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL: Safety and efficacy of longterm treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-2171
34. Tucker EI, Marzec UM, Berny MA, Hurst S, Bunting S, McCarty OJ, Gruber A, Hanson SR: Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates. Sci Transl Med 2010; 2: 37ra45
35. Segre E, Pigozzi L, Lison D, Pivetta E, Bosco O, Vizio B, Suppo U, Turvani F, Morello F, Battista S, Moiraghi C, Montrucchio G, Lupia E: May thrombopoietin be a useful marker of sepsis severity assessment in patients with SIRS entering the emergency department? Clin Chem Lab Med 2014; 52: 1479-1483
36. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, Metelli MR, Giovannini L, Tetta C, Palla R: C reactive protein in patients with chronic renal diseases. Ren Fail 2001; 23: 551-562
37. Perreault M, Roke K, Badawi A, Nielsen DE, Abdelmagid SA, El-Sohemy A, Ma DW, Mutch DM: Plasma levels of 14: 0, 16: 0, 16: 1n-7, and 20: 3n-6 are positively associated, but 18: 0 and 18: 2n-6 are inversely associated with markers of inflammation in young healthy adults. Lipids 2014; 49: 255-263.